Dr Reddy's Laboratories Ltd ADR
RDY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$86.00 | Yfsp | Jypffjgfl |
Dr. Reddy's Earnings: Ends Year With Good Recovery, Strong Launches; Maintaining $60 Fair Value
Dr. Reddy’s Laboratories posted solid fiscal 2023 fourth-quarter results as new product launches more than offset pricing losses and the decline in vaccine sales. The fiscal year ended roughly in line with our expectations, so we are maintaining our $60 fair value estimate and narrow moat rating.